Controversy surrounding new drugs for the treatment of dementia. An unfavourable view;Controversias en torno a los nuevos fármacos en el tratamiento de la demencia. Postura desfavorable

Revista de Neurologia

Volumn 32, Issue 2, 2001, Pages 172-175

  Guardado Santervas P ^a  

^a HOSPITAL TORRECÁRDENAS   (Spain)

Author keywords

Anticholinesterase drugs; Controversy; Dementia; Donepezil; Phannaco economy; Rivastigmine; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR;

DEMENTIA; HUMAN; REVIEW;

CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS;

EID: 0035895372     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3202.2000225     Document Type: Article

References (14)

1. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neural Neurosurg Psychiatry 1999; 66: 137-47.
2. Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459-96.
3. Davies P, Maloney AJF. Selective loss of central cholinergic neurones in Alzheimer's disease. Lancet 1976; 2: 1403.
4. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17.
5. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurones in basal forebrain. Science 1982; 215: 1237-9.
6. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40: 503-9.
7. Drachman DA, Leavitt J. Human memory and the cholinergic system. Arch Neural 1974; 30: 113-21.
8. Duane MP, Hartley LR. Scopolamine and the control of attention in humans. Psychopharmacology 1986; 89: 94-7.
9. Sadot E, Gurwitz D, Barg J, et al. Activation of ml muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC 12 cells. J Neurochem 1996; 66: 877-80.
10. Cummings JL, Vinters HV, Cole GM, Zaven S. Etiologies, palhophysiology, cognitive reserve, and treatment opportunities. Neurology 1998; 51 (Suppl 1): S2-S17.
11. Kish SJ, Robitaille Y, El-Awar M, et al. Non-Alzheimer-type pattern of brain choline acetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy. Ann Neurol 1989; 26: 362-7.
12. Whitehouse PJ, Martion AM, et al. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch Neurol 1988; 45: 722-4.
13. Palmer AM, Procter AW, Stratmann GC, et al. Excitatory amino acid-releasing and cholinergic neurones in Alzheimer's disease. Neurosci Lett 1986; 66: 199-204.
14. Palmer AM, Gershon S. Is the neurochemical basis of Alzheimer's disease cholinergic or glutamatergic? FASEB 1990; 4: 2745-52.